Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Jun 9, 2016 NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced  the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succ...
Jun 1, 2016 NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences: ...
May 27, 2016 First new medicine for PBC in nearly 20 years Investor conference call Tuesday, May 31 at 8:30 a.m. ET NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and ...
May 18, 2016 NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with prim...
May 5, 2016 NEW YORK, May 05, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the quarter ended March 3...
Apr 28, 2016 NEW YORK, April 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ ...
Apr 16, 2016 NEW YORK, April 16, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the winners of its Practice to Policy Health Awards Prog...
Apr 14, 2016 NEW YORK, April 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the results of two new analyses of the POISE trial, the Phase 3 trial of ...
Apr 7, 2016 PDUFA Date is May 29, 2016 Intercept to host investor conference call today at 5:30 p.m. ET NEW YORK, April 07, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical ...
Mar 30, 2016 NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that multiple abstracts evaluating obeticholic acid (OCA) in patients with ...
Page:
1
... NextLast
= add release to Briefcase